Study of SUN-627 for progressive multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests an experimental medicine called SUN-627 for people with progressive multiple sclerosis (MS) that is not currently flaring up. The goal is to see if it can slow down worsening disability without causing serious side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a diagnosis of primary progressive MS or non-active secondary progressive MS.
- You have not had any MS relapses (flare-ups) in the last 2 years.
- Your MS has continued to get worse over time, even without relapses.
- Your level of disability meets the study's minimum requirement.
- You are not currently using certain MS medications or participating in another research study, and you do not have unstable heart conditions or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
This study tests an experimental treatment called C-CAR168, which uses your own immune cells that have been modified to target and potentially slow down the progression of multiple sclerosis. It is for younger adults with progressive MS who have not responded well to standard treatments.
This study collects health information and samples from people with multiple sclerosis (MS) in different stages to help develop better tools for managing the disease. By participating, you could help researchers use data science to improve MS care.
This trial tests a new cell therapy (NG01) for people with secondary progressive multiple sclerosis. It aims to see if the treatment can slow or stop disability progression. Participation involves multiple clinic visits and MRI scans.
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
Hear when a new Primary Progressive Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.